[1,4]Dioxan-2-ylmethyl-ethyl-amine | 264254-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: [1,4]Dioxan-2-ylmethyl-ethyl-amine
• 英文别名: N-(1,4-Dioxan-2-ylmethyl)-N-ethylamine；N-(1,4-dioxan-2-ylmethyl)ethanamine
• CAS: 264254-05-9
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: CLHCIYHDEXJKHF-UHFFFAOYSA-N

物化性质

• 沸点：
  206.3±15.0 °C(Predicted)
• 密度：
  0.958±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  [1,4]Dioxan-2-ylmethyl-ethyl-sulfamic acid 在 氢氧化钾 作用下， 反应 1.0h， 生成 [1,4]Dioxan-2-ylmethyl-ethyl-amine
  参考文献：
  名称：

  Synthesis of mono- and bis(aminomethyl)dioxanes fromN-[3-(2-chloroethoxy)-2-hydroxypropyl]sulfamates

  摘要：

  N-Substituted aminomethyl- and 2,5-bis(aminomethyl)-1,4-dioxanes were prepared by cyclization of the corresponding potassium N-[3-(2-chloroethoxy)-2-hydroxypropyl]sulfamates under the action of an alkaline agent followed by alcoholysis of the resulting sulfamic acids.

  DOI：

  10.1007/bf02498276

文献信息

• [EN] NLRP3 MODULATORS<br/>[FR] MODULATEURS DE NLRP3
  申请人：INNATE TUMOR IMMUNITY INC

  公开号：WO2019014402A1

  公开（公告）日：2019-01-17

  The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

  本发明提供了Formula (I)的化合物：(I)其中所有变量均如本文所定义。这些化合物是NLRP3的调节剂，可用作治疗增殖性疾病的药物，例如在受试者（例如人类）中的癌症治疗。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080096887A1

  公开（公告）日：2008-04-24

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了式I的化合物和药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4的定义如本文所述。式I的化合物可用于治疗与细胞增殖有关的疾病和/或疾病，例如癌症、炎症、关节炎、血管生成或类似疾病。本发明还公开了包含本发明化合物的制药组合物和使用这些化合物治疗上述疾病的方法。
• 10a-Azalide Compound
  申请人：Sugimoto Tomohiro

  公开号：US20090281292A1

  公开（公告）日：2009-11-12

  [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae , erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

  【目标】提供一种具有新结构的化合物，对流感嗜血杆菌和红霉素耐药菌（例如耐药肺炎球菌和链球菌）以及传统的红霉素敏感菌具有有效作用。 【解决方案】本发明提供了一种新型10a-氮杂环十六元化合物，其化学式为（I），其药学上可接受的盐或其溶剂化物，或其制备的中间体。该化合物对流感嗜血杆菌、红霉素耐药性肺炎球菌等具有卓越的抗菌活性，因此可以作为治疗传染病的药物。
• BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES
  申请人：Huang Kenneth He

  公开号：US20110034529A1

  公开（公告）日：2011-02-10

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了I式化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4如所定义。I式化合物在治疗与细胞增殖相关的疾病和/或病情，如癌症、炎症、关节炎、血管生成等方面具有用途。本发明还公开了包含本发明化合物的药物组合物及使用这些化合物治疗上述疾病的方法。
• DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2225238B1

  公开（公告）日：2014-09-03